IKT - Inhibikase Therapeutics, Inc

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Inhibikase Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.06M
• Inhibikase Therapeutics GAAP EPS of -$0.16 misses by $0.01, revenue of $0.6M
• Inhibikase Therapeutics GAAP EPS of -$0.72, revenue of $0.1M
• Inhibikase jumps 35% as FDA lifts full clinical hold on lead candidate
• Inhibikase stock rises ~10% as FDA lifts clinical hold on Parkinson's study
• Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $0.01M
• Inhibikase craters 36% as FDA places clinical hold on IkT-148009 201 programs
• Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia
• Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M
• Inhibikase begins mid-stage trial of IKT-148009 for Parkinson's disease following FDA review
• Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $0.05M
• Inhibikase Therapeutics GAAP EPS of -$0.81, revenue of $3.1M
• Inhibikase Therapeutics reports Q3 results
• Inhibikase Therapeutics reports interim results from oral IkT-148009 studies in NHPs
• Inhibikase Therapeutics gets NIH grant for IkT-148009 Multiple System Atrophy trial
• Inhibikase Therapeutics reports Q2 results
• Inhibikase Therapeutics gets FDA clearance for early-stage Parkinson's disease trial
• Clene, Inhibikase Therapeutics leads healthcare gainers; IMV, Tempest Therapeutics among major losers
• Opthea, Kindred Biosciences leads healthcare gainers; Inhibikase Therapeutics, Paratek Pharmaceuticals among major losers
• Inhibikase Therapeutics prices stock offering at $3